Kineticos Life Sciences Management

Inceptor Bio is a biotechnology company that specializes in developing innovative cell therapy solutions aimed at curing difficult-to-treat cancers. The company focuses on enhancing immune cell performance within the tumor microenvironment through novel mechanisms. Inceptor Bio employs a partnership model with university research programs, fostering collaboration on cutting-edge therapeutic approaches in oncology. The integration of their laboratory and manufacturing capabilities with experienced professionals in cell and gene therapy enables the efficient advancement of therapeutics into clinical settings. By identifying, incubating, and accelerating promising technologies, Inceptor Bio seeks to improve treatment outcomes for cancer patients.

Kinvard Bio, established by Kineticos Life Sciences, is a biotechnology company dedicated to combating antimicrobial resistance. It specializes in developing a novel class of antibiotics, known as lincosamides, with differentiated properties. The company's focus is on creating both oral and intravenous formulations to treat severe and chronic drug-resistant infections, including bacterial pneumonia, complicated urinary tract infections, and nontuberculosis mycobacteria lung disease.

Clarametyx Biosciences, Inc. is a biotechnology company founded in 2020 and headquartered in Columbus, Ohio. The company focuses on developing targeted and immune-enabling biologic therapies that address persistent infections associated with biofilms, which are protective layers that shield bacteria and complicate treatment. Clarametyx has created a novel technology platform that allows for the targeting of these biofilms, thereby enhancing immune response and facilitating antibiotic intervention. One of its key products in development is CMTX-001, a humanized monoclonal antibody currently in the late preclinical stage, aimed at treating hospital-acquired pneumonia. Clarametyx Biosciences is dedicated to combating life-threatening infections and reducing antibiotic resistance through its innovative therapeutic solutions.

Experic is a contract development and manufacturing organization (CDMO) that offers comprehensive pharmaceutical supply services, supporting all stages of a product's life cycle, from clinical trials to commercial production. The company specializes in a range of dosing and packaging formats, including capsule filling, powder and pellet dosing, as well as autoinjectors and pen assemblies. With a focus on quality and efficiency, Experic utilizes advanced equipment in its state-of-the-art Class A GMP facility to deliver high-quality products, even for expedited projects. Their services encompass process development, analytical support, clinical trial supply, vendor management, packaging, and logistics solutions. Experic is dedicated to providing personalized, hands-on assistance to clients throughout their development projects, ensuring a tailored approach to meet specific needs.

Orthobond Corp. is a biotechnology company based in North Brunswick, New Jersey, specializing in surface modification technologies for synthetic materials to enhance their biological compatibility. Founded in 2003, the company develops innovative solutions such as self-assembled monolayers of phosphonate, which facilitate biological responses on inorganic implants without relying on biologics. Orthobond's offerings include osteoconductive surface modifications that promote tissue integration and bioresistant technologies designed to prevent infections in permanent implants. Additionally, the company has introduced AI-SAMP anti-infective technology, which targets orthopedic infections by eliminating bacteria upon contact with implant surfaces and preventing biofilm formation. Through these advancements, Orthobond aims to improve the safety and efficacy of medical devices, addressing critical challenges in infection control and tissue integration.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in the research, development, and commercialization of orally available products for fecal microbiota transplantation. By utilizing bacterial communities derived from the human gastrointestinal tract, EnteroBiotix aims to restore health and prevent bacterial infections. The company focuses on creating microbial therapeutics, both allogenic and autologous, designed to address serious unmet medical needs. Its product pipeline includes high-diversity microbiome-modulating drugs tailored to fortify and restore the microbiome, enabling physicians to effectively prevent and treat various debilitating infections and diseases.

Kincell Bio specializes in the development and manufacturing of immune clinical cells to support cell therapy initiatives. The company combines extensive scientific expertise with industry knowledge to provide a comprehensive suite of services, including process and analytical development, CMC assistance, and high-quality clinical cell therapy manufacturing. Kincell Bio employs advanced software tools to facilitate the design, manufacturing, and analysis of cell therapies, complemented by a dedicated manufacturing facility and a team of seasoned professionals. This integrated approach enables researchers and laboratories to expedite the development and delivery of innovative cell therapies to patients.

eXmoor Pharma is a consultancy firm that focuses on technical and strategic solutions in the fields of cell and gene therapies and biopharmaceuticals. The company operates a contract development and manufacturing business tailored for advanced therapy medicinal products (ATMPs). eXmoor Pharma provides a comprehensive suite of services, including manufacturing strategy, process development consultancy, and bioprocess engineering. By collaborating closely with clients, the company assists in designing projects that align with their specific needs and commercial goals, facilitating the advancement of innovative therapeutic solutions.

Experic is a contract development and manufacturing organization (CDMO) that offers comprehensive pharmaceutical supply services, supporting all stages of a product's life cycle, from clinical trials to commercial production. The company specializes in a range of dosing and packaging formats, including capsule filling, powder and pellet dosing, as well as autoinjectors and pen assemblies. With a focus on quality and efficiency, Experic utilizes advanced equipment in its state-of-the-art Class A GMP facility to deliver high-quality products, even for expedited projects. Their services encompass process development, analytical support, clinical trial supply, vendor management, packaging, and logistics solutions. Experic is dedicated to providing personalized, hands-on assistance to clients throughout their development projects, ensuring a tailored approach to meet specific needs.

Inceptor Bio is a biotechnology company that specializes in developing innovative cell therapy solutions aimed at curing difficult-to-treat cancers. The company focuses on enhancing immune cell performance within the tumor microenvironment through novel mechanisms. Inceptor Bio employs a partnership model with university research programs, fostering collaboration on cutting-edge therapeutic approaches in oncology. The integration of their laboratory and manufacturing capabilities with experienced professionals in cell and gene therapy enables the efficient advancement of therapeutics into clinical settings. By identifying, incubating, and accelerating promising technologies, Inceptor Bio seeks to improve treatment outcomes for cancer patients.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in the research, development, and commercialization of orally available products for fecal microbiota transplantation. By utilizing bacterial communities derived from the human gastrointestinal tract, EnteroBiotix aims to restore health and prevent bacterial infections. The company focuses on creating microbial therapeutics, both allogenic and autologous, designed to address serious unmet medical needs. Its product pipeline includes high-diversity microbiome-modulating drugs tailored to fortify and restore the microbiome, enabling physicians to effectively prevent and treat various debilitating infections and diseases.

Kincell Bio specializes in the development and manufacturing of immune clinical cells to support cell therapy initiatives. The company combines extensive scientific expertise with industry knowledge to provide a comprehensive suite of services, including process and analytical development, CMC assistance, and high-quality clinical cell therapy manufacturing. Kincell Bio employs advanced software tools to facilitate the design, manufacturing, and analysis of cell therapies, complemented by a dedicated manufacturing facility and a team of seasoned professionals. This integrated approach enables researchers and laboratories to expedite the development and delivery of innovative cell therapies to patients.